[]
Dinarello C.A.: The biological properties of interleukin-1. Eur Cytokine
Netw 1994; 5: 517–531.
[]
Heyser C.J., Masliah E., Samimi A., et al.: Progressive decline in
avoidance learning paralleled by inflammatory neurodegeneration in
transgenic mice expressing interleukin-6 in the brain. Proc Natl Acad Sci
USA 1997; 94: 1500–1505.
[]
Kalman J., Juhasz A., Laird G., et al.: Serum interleukin-6 levels correlate
with the severity of dementia in Down syndrome and in Alzheimer’s
disease. Acta Neurol Scand 1997; 96: 236–240.
[]
Park E., Alberti J., Mehta P., et al.: Partial impairment of immune
functions in peripheral blood leukocytes from aged men with Down’s
syndrome. Clin Immunol 2000; 95: 62–69.
[]
Meguid N.A., Basheer H.H., Ismail E.A., et al.: Immune dysfunction in
Egyptian children with Down syndrome. Int J Ch Neuropsychiatry 2004;
1: 65–74.
[]
Trotta M.B.F., Azul J.B.S., Wajngarten M., et al.: Inflammatory and
immunological parameters in adults with Down syndrome. Immunity
and Ageing 2011; 8: 4–10.
[]
Dogliotti G., Galliera E., Licastro F., Corsi MM. Age- related changes
in plasma levels of BDNF in Down syndrome patients. Immunity and
Ageing 2010; 7: 2–7.
[]
Corsi M.M., Dogliotti G., Pedroni F., et al.: Plasma nerve growth
factor (NGF) and inflammatory cytokines (IL-6 and mcp-1) in young
and adults subjects with Down syndrome: An interesting pathway.
Neuroendocrinology letters 2006; 27: 773–778.
[]
Griffin W.S., Stanley L.C., Ling C., et al.: Brain interleukin 1 and S-100
immunoreactivity are elevated in Down syndrome and Alzheimer
disease. Proc Natl Acad Sci USA 1989; 86: 7611–7615.
[]
Licastro F., Mariani R.A., Faldella G., et al.: Immune-endocrine status and
coeliac disease in children with Down’s syndrome: relationships with
zinc and cognitive efficiency. Brain Res Bull 2001; 55: 313–317.
[]
Castle S.C.: Clinical Relevance of Age-Related Immune Dysfunction. Clin
Infect Dis. 2000; 31: 578–585.
[]
Chandra R.K.: Effect of vitamin and trace-element supplementation on
immune responses and infection in elderly subjects. Lancet 1992; 340:
1124–1127.
[]
Miller R.A.: Aging and immune function. Int Rev Cytol 1991; 124: 187–215.
[]
Burns E.A., Leventhal E.A.: Aging, Immunity, and Cancer. Cancer Control
2000; 7: 513– 522.
[]
Licastro F., Chiappelli M., Ruscica M., et al.: Altered cytokine and
acute phase response protein levels in the blood of children with
Downs syndrome: relationship with dementia of Alzheimer’s type. Int J
Immunopathol Pharmacol 2005; 18: 165–172.
[]
Tartaglia L.A., Weber R.F., Figari I.S., et al.: The two different receptors
for tumor necrosis factor mediate distinct cellular responses. Proc Natl
Acad Sci USA 1991; 88: 9292–9296.
[]
Godfried M.H., van der Poll T., Jansen J., et al.: Soluble receptors for
tumor necrosis factor: a putative marker of disease progression in HIV
infection. AIDS 1993; 7: 33–36.
[]
Śmigielska-Kuzia J., Boćkowski L., Sobaniec W., et al.: Anti-inflammatory
plasma cytokines in children and adolescents with Down syndrome.
Folia Histochemica et Cytobiologica 2010; 48: 667–670.
[]
Chistiakov D.: Down syndrome and coexistent autoimmune diseases. J.
Appl Biomed 2007; 5: 71–76.
[]
Marder E., Dennis J.: Medical management of children with Down’s
syndrome. Current Pediatr 1997; 7: 1–7.
[]
Śmigielska-Kuzia J., Sobaniec W., Kułak W., et al.: Antioxidant enzymes
and lipid peroxides in children with Down syndrome. J Pediatr Neurol
2007; 5: 117–120.
[]
Cholewa M., Śmigielska- Kuzia J., Sendrowski K., et al. Evaluation of
antioxidant activity In the erythrocytes in patients with Down syndrome.
Neurol. Dziec. 2011; 20: 43–47.
[]
Stafstrom C.E., Patxot D.F., Gilmore H.E., et al.: Seizures in children with
Down syndrome: etiology, characteristics and outcome. Dev Med Child
Neurol 1991; 33: 191–200.
[]
Ekstein S., Glick B., Weill M., et al.: Down Syndrome and Attention-
Deficit/Hyperactivity Disorder (ADHD ). J Child Neurol 2011; 26: 1290–
1295.
[]
Śmigielska-Kuzia J., Sobaniec W., Kułak W., et al.: Clinical and EEG
Features of Epilepsy in children and adolescents in Down syndrome. J
Child Neurol 2009; 24: 416–420.
[]
Jakubiuk-Tomaszuk A., Śmigielska- Kuzia J., Wysocka J., et al.:
Assessment of cellular immunity In children with Down syndrome by
determining the ratio of subpopulations of T lymphocytes CD3+, CD4+
and CD8+ in peripheral blood using flow cytometric method. Neurol.
Dziec. 2011; 20: 49–53.
[]
Nespoli L., Burgio G.R., Ugazio A.G., et al.: Immunological features of
Down syndrome: a review. J Intellect Disabil Res 1993; 37: 543–551.
[]
Mark R.E., Griffin W.S.: Trisomy 21 and the brain. J Neuropathol Exp
Neurol 2004; 63: 679–685.
[]
Kinik S.T., Ozcay F., Varan B.: Type I diabetes mellitus, Hashimoto’s
thyroiditis and celiac disease in an adolescent with Down syndrome.
Pediatr Int 2006; 48: 433–435.
[]
Weijerman M.E., de Winter J.P.: Clinical practice. The care of children
with Down syndrome. Eur J Pediatr 2010; 169: 1445–1452.
[]
Gibson P.A., Newton R.W., Selby K., et al.: Longitudinal study of
thyroid function in Down’s syndrome in the first two decades. Arch Dis
Child 2005; 09: 575–578.
[]
Wouters J., Weijerman M.E., Furth A.M., et al.: Prospective HLA,
EMA, and TGA testing celiac disease in children with Down syndrome.
J Pediatrics 2009; 154: 239–242.
[]
Zwaan M.C., Reinhardt D.R., Hizler J., et al.: Acute leukemias in children
with Down syndrome. Pediatr Clin North Am 2008; 55: 53–70.
[]
Kenis G., Teunissen Ch., De Jongh R., et al.: Stability of interleukin 6,
soluble interleukin 6 receptor, interleukin 10, and CC16 in human serum.
Cyctokine 2002; 19: 228–235.
[]
Carta M.G., Serra P., Ghiani A., et al.: Chemokines and pro-inflammatory
cytokines in Down’s syndrome: an early marker for Alzheimer-type
dementia? Psychother Psychosom 2002; 71: 233–236.
[]
Sutinen E.M., Pirttilä T., Anderson G., et al.: Pro-inflammatory
interleukin-18 increases Alzheimer’s disease-associated amyloid-β
production in human neuron-like cells. J Neuroinflammation 2012; 9:
199–212.
Scholar Google
PubMed